# Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

> **NCT02614586** · PHASE1 · TERMINATED · sponsor: **Takeda** · enrollment: 11 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** TAK-058
- **DRUG:** Ondansetron
- **DRUG:** TAK-058 Placebo
- **DRUG:** Ondansetron Placebo

## Key facts

- **NCT ID:** NCT02614586
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614586, "Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02614586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*